keyword
MENU ▼
Read by QxMD icon Read
search

Crohns disease and ulcerative colitis

keyword
https://www.readbyqxmd.com/read/29792883/plasma-n-glycan-signatures-associate-with-features-of-inflammatory-bowel-diseases
#1
Florent Clerc, Mislav Novokmet, Viktoria Dotz, Karli R Reiding, Noortje de Haan, Guinevere S M Kammeijer, Hans Dalebout, Marco R Bladergroen, Frano Vukovic, Erdmann Rapp, Stephan R Targan, Gildardo Barron, Natalia Manetti, Anna Latiano, Dermot P B McGovern, Vito Annese, Gordan Lauc, Manfred Wuhrer
BACKGROUND & AIMS: Biomarkers are needed for early detection of Crohn's disease (CD) and ulcerative colitis (UC) or to predict patient outcomes. Glycosylation is a common and complex post-translational modification of proteins that affects their structure and activity. We compared plasma N-glycosylation profiles between patients with CD or UC and healthy individuals (controls). METHODS: We analyzed the total plasma N-glycomes of 2635 patients with inflammatory bowel diseases and 996 controls by mass spectrometry with a linkage-specific sialic acid derivatization technique...
May 21, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29791048/long-term-course-of-inflammatory-bowel-disease-after-the-great-east-japan-earthquake
#2
Teruko Miyazawa, Hisashi Shiga, Yoshitaka Kinouchi, Seiichi Takahashi, Gen Tominaga, Hiroki Takahashi, Sho Takagi, Nobuya Obana, Tatsuya Kikuchi, Shinya Omori, Yuichirou Sato, Shuichiro Takahashi, Ken Umemura, Katsuya Endo, Yoichi Kakuta, Masaki Matsuura, Tomoya Kimura, Masatake Kuroha, Tooru Shimosegawa
BACKGROUND AND AIM: This study analyzed inflammatory bowel disease activity for two years after the Great East Japan Earthquake. METHODS: We compared the relapse rates of patients with ulcerative colitis or Crohn's disease 1 and 2 years after the earthquake with rates immediately after the earthquake. To evaluate continuous disease courses, we also performed multivariate time-to-event analyses from the time of the earthquake to the onset of additional treatments...
May 23, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29790793/increased-arterial-stiffness-similar-findings-in-patients-with-inflammatory-bowel-disease-without-prior-hypertension-or-diabetes-and-in-patients-with-well-controlled-hypertension
#3
Radovan Prijić, Vedran Premužić, Marko Brinar, Željko Krznarić, Bojan Jelaković, Silvija Čuković-Čavka
PURPOSE: Chronic inflammatory diseases are related with earlier onset of atherosclerosis. We hypothesized that inflammatory bowel disease patients with chronic, systemic inflammation have an increased arterial stiffness associated with the disease duration. Also, we wanted to compare arterial stiffness markers between inflammatory bowel disease and well-controlled hypertension patients. MATERIALS AND METHODS: A total of 89 inflammatory bowel disease patients (60 patients with Crohn's disease and 29 patients with ulcerative colitis, age range 20-64 years) without history of arterial hypertension or diabetes were enrolled and age matched with a control group of patients (73 patients, age range 25-69 years, 41 (56...
May 23, 2018: Blood Pressure
https://www.readbyqxmd.com/read/29789682/the-role-of-diet-in-the-aetiopathogenesis-of-inflammatory-bowel-disease
#4
REVIEW
Hamed Khalili, Simon S M Chan, Paul Lochhead, Ashwin N Ananthakrishnan, Andrew R Hart, Andrew T Chan
Crohn's disease and ulcerative colitis, collectively known as IBD, are chronic inflammatory disorders of the gastrointestinal tract. Although the aetiopathogenesis of IBD is largely unknown, it is widely thought that diet has a crucial role in the development and progression of IBD. Indeed, epidemiological and genetic association studies have identified a number of promising dietary and genetic risk factors for IBD. These preliminary studies have led to major interest in investigating the complex interaction between diet, host genetics, the gut microbiota and immune function in the pathogenesis of IBD...
May 22, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29788469/influences-and-impact-of-anxiety-and-depression-in-the-setting-of-inflammatory-bowel-disease
#5
Seyedehsan Navabi, Venkata Subhash Gorrepati, Sanjay Yadav, Jaykrishna Chintanaboina, Sarah Maher, Peter Demuth, Benjamin Stern, August Stuart, Andrew Tinsley, Kofi Clarke, Emmanuelle D Williams, Matthew D Coates
Background: Individuals with inflammatory bowel disease (IBD) are at increased risk of developing anxiety or depression (A&D). Crohn's disease (CD) and ulcerative colitis (UC) with comorbid A&D are both more challenging to manage. IBD providers need to better understand the causes and impact of A&D in order to improve care for IBD patients. We sought to identify clinical factors that influence development of A&D and healthcare utilization in IBD. Methods: This is a retrospective analysis using an IBD natural history registry from a single tertiary care referral center...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788410/differentiation-between-pediatric-irritable-bowel-syndrome-and-inflammatory-bowel-disease-based-on-fecal-scent-proof-of-principle-study
#6
Sofie Bosch, Nora van Gaal, Roy P Zuurbier, James A Covington, Alfian N Wicaksono, Maarten H Biezeveld, Marc A Benninga, Chris J Mulder, Nanne K H de Boer, Tim G J de Meij
Background: The diagnostic work-up of pediatric irritable bowel syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) commonly includes invasive tests for discrimination from inflammatory bowel disease (IBD). As this carries a high burden on patients, an ongoing need exists for development of noninvasive diagnostic biomarkers for IBS and FAP-NOS. Several studies have shown microbiota alterations in IBS/FAP, which are considered to be reflected by fecal volatile organic compounds (VOCs)...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788385/systematic-review-and-meta-analysis-vedolizumab-and-postoperative-complications-in-inflammatory-bowel-disease
#7
Diana E Yung, Nir Horesh, Amy L Lightner, Shomron Ben-Horin, Rami Eliakim, Anastasios Koulaouzidis, Uri Kopylov
Background: Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD) patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-analysis aims to evaluate the risk of postoperative complications in IBD patients preoperatively exposed to VDZ in comparison with patients exposed to anti-tumor necrosis factor (anti-TNF) treatment or no biologic therapy. Methods: A systematic review with a meta-analysis of the existing literature was conducted...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788318/effectiveness-and-safety-of-vedolizumab-in-anti-tnf-na%C3%A3-ve-patients-with-inflammatory-bowel-disease-a-multicenter-retrospective-european-study
#8
Uri Kopylov, Bram Verstockt, Luc Biedermann, Shaji Sebastian, Daniela Pugliese, Elena Sonnenberg, Peter Steinhagen, Naila Arebi, Yulia Ron, Torsten Kucharzik, Xavier Roblin, Bella Ungar, Ariella Bar-Gil Shitrit, Sandro Ardizzone, Pauliina Molander, Marina Coletta, Laurent Peyrin-Biroulet, Peter Bossuyt, Irit Avni-Biron, Emmanouela Tsoukali, Mariangela Allocca, Konstantinos Katsanos, Tim Raine, Taina Sipponen, Gionata Fiorino, Shomron Ben-Horin, Rami Eliakim, Alessandro Armuzzi, Britta Siegmund, Daniel C Baumgart, Nikolaos Kamperidis, Nitsan Maharshak, Christian Maaser, Gerassimos Mantzaris, Henit Yanai, Dimitrious K Christodoulou, Iris Dotan, Marc Ferrante
Background: Vedolizumab (VDZ) is effective for treatment of ulcerative colitis (UC) and Crohn's disease (CD). In GEMINI trials, anti-tumor necrosis factor (anti-TNF)-naïve patients had a superior response compared with anti-TNF-exposed patients. In real-world experience (RWE), the number of included anti-TNF-naïve patients was low. We aimed to evaluate the effectiveness and safety of VDZ in anti-TNF-naïve patients in an RWE setting. Methods: This retrospective multicenter European pooled cohort study included consecutive active anti-TNF-naïve IBD patients treated with VDZ...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788306/pregnancy-onset-inflammatory-bowel-disease-a-subtle-diagnosis
#9
Benjamin Koslowsky, Sorina Grisaru-Granovsky, Dan Meir Livovsky, Yael Milgrom, Eran Goldin, Ariella Bar-Gil Shitrit
Background: Inflammatory bowel diseases (IBDs) are commonly diagnosed during the reproductive years. IBD first manifested during pregnancy (pregnancy-onset IBD [POIBD]) is still an undescribed entity. The aim of the study was to evaluate the characteristics and maternal and neonatal outcomes of patients with POIBD. Methods: Data of all pregnant women with IBD within a single multidisciplinary referral clinic, IBD-MOM, between 2011-2016, were analyzed. Maternal and neonatal characteristics and outcomes were compared between the POIBD group and those diagnosed before pregnancy (non-POIBD)...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788272/therapeutic-drug-monitoring-with-ustekinumab-and-vedolizumab-in-inflammatory-bowel-disease
#10
Sophie Restellini, Reena Khanna, Waqqas Afif
In patients with Crohn's disease (CD) and ulcerative colitis (UC), the use of therapeutic drug monitoring (TDM) with TNF-α antagonists has led to a personalized approach to optimize treatment and has been shown to be cost-effective. The utility of this TDM-based personalized approach for novel biologic agents, which target different inflammatory pathways, is unclear. Commercial assays for ustekinumab (UST) and vedolizumab (VDZ) are available, but there is little available guidance for clinicians regarding the use of TDM with these drugs...
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788260/impact-of-obesity-on-short-and-intermediate-term-outcomes-in-inflammatory-bowel-diseases-pooled-analysis-of-placebo-arms-of-infliximab-clinical-trials
#11
Siddharth Singh, James Proudfoot, Ronghui Xu, William J Sandborn
Background and aims: To assess whether obesity may affect natural history of inflammatory bowel diseases (IBD), we conducted an individual participant data (IPD) pooled analysis of placebo arms, using data from clinical trials of infliximab in IBD and using the Yale Open Data Access (YODA) Project. Methods: We obtained IPD from 4 placebo-controlled trials of infliximab in adults with IBD (ACCENT-I and ACCENT-II; ACT-1 and ACT-2). Patients were categorized into quartiles based on body mass index (BMI) or weight at time of trial entry...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788248/respiratory-tract-infections-in-patients-with-inflammatory-bowel-disease-safety-analyses-from-vedolizumab-clinical-trials
#12
Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake, Simon P L Travis
Background and Aims: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods: Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab in ulcerative colitis [UC; GEMINI 1] and Crohn's disease [CD; GEMINI 2], and a long-term safety study [UC and CD] were pooled...
May 17, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29788240/predictors-and-management-of-loss-of-response-to-vedolizumab-in-inflammatory-bowel-disease
#13
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, Prianka Chilukuri, Joseph Meserve, Khadija Chaudrey, Jenna L Koliani-Pace, Robert Hirten, David Faleck, Morris Barocas, Michelle Luo, Karen Lasch, Brigid S Boland, Siddharth Singh, Niels Vande Casteele, Sashidhar Varma Sagi, Monika Fischer, Shannon Chang, Matthew Bohm, Dana Lukin, Keith Sultan, Arun Swaminath, David Hudesman, Nitin Gupta, Sunanda Kane, Edward V Loftus, William J Sandborn, Corey A Siegel, Bruce E Sands, Jean-Frederic Colombel, Bo Shen, Parambir S Dulai
Background: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods: Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used to determine rates of LOR to VDZ . Independent predictors of LOR were identified using univariate and multivariable Cox proportional hazard regression...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788234/prediagnostic-serum-vitamin-d-levels-and-the-risk-of-crohn-s-disease-and-ulcerative-colitis
#14
Cong Dai, Min Jiang, Ming-Jun Sun
No abstract text is available yet for this article.
May 17, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788186/nanoparticle-based-oral-drug-delivery-systems-targeting-the-colon-for-treatment-of-ulcerative-colitis
#15
Mingzhen Zhang, Didier Merlin
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic relapsing inflammation of the gastrointestinal tract. Delivery of orally administered drugs to the colon is highly desirable for the treatment of UC, as it improves their efficacy while reducing systemic toxicity. However, the targeting of oral drugs to the colon, which is located at the distal end of the gastrointestinal tract, is difficult due to physiological challenges, biochemical barriers, and environmental barriers, including those associated with mucus and epithelium...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788069/inflammatory-bowel-disease-and-parkinson-s-disease-a-nationwide-swedish-cohort-study
#16
Petra Weimers, Jonas Halfvarson, Michael C Sachs, Rachel Saunders-Pullman, Jonas F Ludvigsson, Inga Peter, Johan Burisch, Ola Olén
Background: Few studies have examined the association between inflammatory bowel disease (IBD) and Parkinson's disease (PD). Methods: To estimate the incidence and relative risk of PD development in a cohort of adult IBD, we included all incident IBD patients (n = 39,652) in the Swedish National Patient Register (NPR) between 2002 and 2014 (ulcerative colitis [UC]: n = 24,422; Crohn's disease [CD]: n = 11,418; IBD-unclassified [IBD-U]: n = 3812). Each IBD patient was matched for sex, age, year, and place of residence with up to 10 reference individuals (n = 396,520)...
May 16, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29788063/lack-of-difference-in-treatment-patterns-and-clinical-outcomes-between-black-and-white-patients-with-inflammatory-bowel-disease
#17
Edward L Barnes, Bharati Kochar, Millie D Long, Joel Pekow, Ashwin Ananthakrishnan, Adjoa Anyane-Yeboa, Christopher Martin, Joseph Galanko, Hans H Herfarth, Michael D Kappelman, Robert S Sandler
Background: Previous reports have shown differences in phenotypes among black patients with inflammatory bowel disease (IBD) compared with other racial groups, but prior studies were limited by small numbers of black patients and cross-sectional analyses. We used data from the Sinai-Helmsley Alliance for Research Excellence cohort to compare phenotypes and treatment patterns of black and white patients with IBD in a prospective study. Methods: We compared phenotypes, IBD-specific therapies, and health care utilization among black and white patients with IBD...
May 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29787362/j-pouch-imaging-findings-surgical-variations-natural-history-and-common-complications
#18
Joshua D Reber, John M Barlow, Amy L Lightner, Shannon P Sheedy, David H Bruining, Christine O Menias, Joel G Fletcher
Ileal pouch-anal anastomosis, or J pouch, surgery has become the procedure of choice for treatment of medically refractory ulcerative colitis and familial adenomatous polyposis. Overall, this operation is associated with a low rate of postoperative morbidity and good long-term function. However, when complications develop, there is a heavy reliance on imaging to facilitate an accurate diagnosis. Reported postoperative complication rates range from 5% to 35%. Complications generally can be categorized as structural, inflammatory, or neoplastic conditions...
May 25, 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29780594/role-of-endoscopy-in-inflammatory-bowel-disease
#19
REVIEW
Shishira Bharadwaj, Neeraj Narula, Parul Tandon, Mohammad Yaghoobi
Crohn's disease (CD) and ulcerative colitis (UC) constitute the two most common phenotypes of inflammatory bowel disease (IBD). Ileocolonoscopy with biopsy has been considered the gold standard for the diagnosis of IBD. Differential diagnosis of CD and UC is important, as their medical and surgical treatment modalities and prognoses can be different. However, approximately 15% of patients with IBD are misdiagnosed as IBD unclassified due to the lack of diagnostic certainty of CD or UC. Recently, there has been increased recognition of the role of the therapeutic endoscopist in the field of IBD...
May 2018: Gastroenterology Report
https://www.readbyqxmd.com/read/29780153/food-specific-iggs-are-highly-increased-in-the-sera-of-patients-with-inflammatory-bowel-disease-and-are-clinically-relevant-to-the-pathogenesis
#20
Nanping Xiao, Fenghua Liu, Guangxi Zhou, Mingming Sun, Fengfu Ai, Zhanju Liu
Objective Dietary antigens are common luminal antigens in the gastrointestinal tract and have been considered to contribute to the pathogenesis of inflammatory bowel disease (IBD). We analyzed the levels of food-specific IgGs against a variety of dietary antigens, explored the clinical relevance of food allergy to the pathogenesis of IBD, and investigated whether or not infliximab (IFX) treatment could regulate the immune responses induced by dietary antigens. Methods A total of 301 IBD patients, including 201 patients with Crohn's disease (CD) and 100 patients with ulcerative colitis (UC), were recruited, and their serum food-specific IgGs against 14 food antigens were detected by a semi-quantitative enzyme linked immunosorbent assay (ELISA)...
May 18, 2018: Internal Medicine
keyword
keyword
63595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"